BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 16438941)

  • 1. Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells.
    Krkoška M; Paruch K; Šošolíková T; Vázquez-Gómez G; Herůdková J; Novotný J; Ovesná P; Sova P; Hyršlová Vaculová A
    Biol Chem; 2024 Jun; 405(6):395-406. PubMed ID: 38452398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micelle-in-Liposomes for Sustained Delivery of Anticancer Agents That Promote Potent TRAIL-Induced Cancer Cell Apoptosis.
    Zhang Z; Patel SB; King MR
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells.
    Corno C; Arrighetti N; Ciusani E; Corna E; Carenini N; Zaffaroni N; Gatti L; Perego P
    Front Cell Dev Biol; 2020; 8():610. PubMed ID: 32754596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
    Chen Z; Liu Z; Huang W; Li Z; Zou J; Wang J; Lin X; Li B; Chen D; Hu Y; Ji J; Gao J; Shen L
    J Transl Med; 2017 Dec; 15(1):253. PubMed ID: 29237470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
    Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.
    Van Geelen CM; de Vries EG; de Jong S
    Drug Resist Updat; 2004 Dec; 7(6):345-58. PubMed ID: 15790545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma and TRAIL in human breast tumor cells.
    Ruiz de Almodóvar C; López-Rivas A; Ruiz-Ruiz C
    Vitam Horm; 2004; 67():291-318. PubMed ID: 15110183
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.